Videos

100 years of experience in intellectual property rights Valea’s vision is to be regarded as one of Europe’s leading consulting firms in the field of intellectual property rights, and to be the natural choice for companies that work proactively to optimise the return on their intangible assets. view now

100 years of experience in intellectual property rights Valea’s vision is to be regarded as one of Europe’s leading consulting firms in the field of intellectual property rights, and to be the natural choice for companies that work proactively to optimise the return on their intangible assets. view now

100 years of experience in intellectual property rights Valea’s vision is to be regarded as one of Europe’s leading consulting firms in the field of intellectual property rights, and to be the natural choice for companies that work proactively to optimise the return on their intangible assets. view now

100 years of experience in intellectual property rights Valea’s vision is to be regarded as one of Europe’s leading consulting firms in the field of intellectual property rights, and to be the natural choice for companies that work proactively to optimise the return on their intangible assets. view now

100 years of experience in intellectual property rights Valea’s vision is to be regarded as one of Europe’s leading consulting firms in the field of intellectual property rights, and to be the natural choice for companies that work proactively to optimise the return on their intangible assets. view now

"Wherever you sit in the world as a regulator, most of the clinical trials you receive in marketing applications, most of the manufacturing that takes place for products is taking place in territories outside of the juristic ion of your regulatory system," said Fergus Sweeney, Head of Compliance & Inspection Patient Health Protection, European Medicines Agency (EMA). view now

Dr. Hans-Georg Eichler, Senior Medical Officer for the European Medicines Agency, talks about the Agency's growth, starting a common language between payers and regulators and the EMA's top priorities over the next few years. view now

The EMA's Sabine Brosch, speaks about collecting adverse drug reaction data worldwide, the importance of setting international standards for pharmacovigilance and collaborating to address global issues. Brosch also discusses how the EMA is working to improve pharmacovigilance, the impact of new legislation and social media and miscommunication. view now

In this presentation Grant Courtney, Global Serialisation Lead (GSK), EFPIA Representative gives an introduction to the approaches that were tested during the EFPIA pilot in Sweden and evaluates the results of the pilot and how they can be translated to create a best practice approach to mass serialisation. view now

Harry Rotgans, Head of investigation, Netherlands Health Care Inspectorate discusses insights into inspection and enforcement and optimisation of supply chain partners and governments working together view now

Coding, serialisation and traceability/track & trace are proposed as solutions by governments and technology providers but un-coordinated and conflicting coding requirements, competing technologies, scope and timescale challenges, standards that are not yet fully emerged and conflicts between data integrity, security, packaging performance all add to the challenge for the industry. view now